|
|
Profile
|
Delegates :
Masaaki Matsubara |
|
Incorporated :
February 8 , 2007 |
Paid in Capital :
19 Million yen |
Employees :
13 人 |
Address :
9F 2-1 Shimokawabatamachi, Hakata-ku FUKUOKA
〒8120027
|
TEL/FAX :
092-271-5508 / 092-282-1164 |
URL：
https://www.sentan.co.jp/en/ |
Attachment :
|
Mission/Background :
We are a drug discover biotechnology venture company, and conduct R&D of a nanoparticle formulation mainly focused on cardiovascular diseases with nanotechnology as the critical technology. In addition, we are carrying out the development of new health foods in an efficient and scientific way by effectively utilizing the unique know-how and human resources that we have cultivated through R&D of pharmaceutical products. |
|
Technology & Business
|
Our nanoparticles and micro-particles can be used as bioabsorbable polymers. In particular, “PLGA,” which is commonly used, is a copolymer of lactic acid and glycolic acid, and is a safe and secure polymer that is absorbed in the body and then, finally metabolized as water and carbon dioxide.
Using our unique nano-microparticle technology, we work on drug discovery research. preventive medicine (foods/supplements) and animal feed.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Pitavastatin-Nano particle
|
Preclinical
|
Pigmentary degeneration of the retina, Age-related macular degeneration
|
Investigator-initiated (clinical) trial
|
Pitavastatin-Nano particle
|
Preclinical
|
Feline renal failure
|
|
Genmai Foodicle
|
Launched
|
|
|
Animal feed
|
Discovery
|
Nonosized particles for animal feed
|
|
Cyclosporin-Nano particle
|
Preclinical
|
Acute myocardial infarction, stroke
|
|
|
Highlights
|
Under Construction
|
|
Alliance strategy
|
Under Construction
|
|
|